226 related articles for article (PubMed ID: 8978794)
21. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.
Pratt CB; Roberts D; Shanks EC; Warmath EL
Cancer Res; 1974 Dec; 34(12):3326-31. PubMed ID: 4547680
[No Abstract] [Full Text] [Related]
22. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
25. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity.
Nirenberg A; Mosende C; Mehta BM; Gisolfi AL; Rosen G
Cancer Treat Rep; 1977 Aug; 61(5):779-83. PubMed ID: 302143
[No Abstract] [Full Text] [Related]
26. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
[TBL] [Abstract][Full Text] [Related]
28. [Effect of rescue treatment with high doses of methotrexate (MTX) followed by leucovorin (LV) on neoplastic cells (HeLa line) and normal sensitized peripheral lymphocytes].
Ruano A; Alvarez-Rodríguez Y; Valladares Y
Rev Esp Oncol; 1982; 29(4):665-73. PubMed ID: 6985426
[TBL] [Abstract][Full Text] [Related]
29. Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
Punt CJ
Semin Oncol; 2000 Oct; 27(5 Suppl 10):88-90. PubMed ID: 11049038
[No Abstract] [Full Text] [Related]
30. High-dose methotrexate-doxycycline interaction.
Tortajada-Ituren JJ; Ordovás-Baines JP; Llopis-Salvia P; Jiménez-Torres NV
Ann Pharmacother; 1999; 33(7-8):804-8. PubMed ID: 10466909
[TBL] [Abstract][Full Text] [Related]
31. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
32. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
Cole PD; Smith AK; Kamen BA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era.
Schilsky RL
Stem Cells; 1996 Jan; 14(1):29-32. PubMed ID: 8820948
[TBL] [Abstract][Full Text] [Related]
34. Treatment of solid Gardner lymphosarcoma with methotrexate sorbed on 2-hydroxyethylmethacrylate polymer in combination with leukovorin.
Motycka K; Slavík K; Balcarbová A; Cihar R; Spacek P; Kubín M
Neoplasma; 1978; 25(2):217-25. PubMed ID: 306074
[TBL] [Abstract][Full Text] [Related]
35. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
36. [Management recommendations in patients with methotrexate intoxication].
Schellens JH; Beijnen JH
Ned Tijdschr Geneeskd; 2007 Feb; 151(6):337-41. PubMed ID: 17352296
[TBL] [Abstract][Full Text] [Related]
37. Biomodulation of 5-fluorouracil with antifolates.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
[TBL] [Abstract][Full Text] [Related]
38. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.
Estève MA; Devictor-Pierre B; Galy G; André N; Coze C; Lacarelle B; Bernard JL; Monjanel-Mouterde S
Eur J Clin Pharmacol; 2007 Jan; 63(1):39-42. PubMed ID: 17115148
[No Abstract] [Full Text] [Related]
39. How to rescue high-dose methotrexate induced nephrotoxicity and literature review about hemodiafiltration?
Yang YY; Gao L; Ding N; Wang XB; Zhang LP; Gao LH; Wang Z
Pak J Pharm Sci; 2020 May; 33(3):1163-1167. PubMed ID: 33191243
[TBL] [Abstract][Full Text] [Related]
40. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
